Cardiome Pharma Corp (NASDAQ:CRME) (TSE:COM) – Analysts at Zacks Investment Research issued their FY2017 earnings estimates for shares of Cardiome Pharma in a research note issued on Monday. Zacks Investment Research analyst J. Vandermosten forecasts that the biopharmaceutical company will post earnings of ($0.81) per share for the year. Zacks Investment Research currently has a “Hold” rating on the stock. Zacks Investment Research also issued estimates for Cardiome Pharma’s Q4 2017 earnings at ($0.16) EPS, FY2018 earnings at ($0.66) EPS and FY2019 earnings at ($0.59) EPS.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last issued its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The firm had revenue of $6.02 million for the quarter, compared to the consensus estimate of $7.42 million. Cardiome Pharma had a negative net margin of 112.91% and a negative return on equity of 94.68%. The business’s revenue was up 14.9% on a year-over-year basis. During the same period last year, the company posted ($0.19) earnings per share.

CRME has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $9.50 price objective on shares of Cardiome Pharma in a research note on Wednesday, November 22nd. Mackie raised shares of Cardiome Pharma to a “buy” rating in a research note on Friday, December 15th. Finally, Canaccord Genuity set a $5.00 price target on shares of Cardiome Pharma and gave the stock a “buy” rating in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $5.50.

Cardiome Pharma (CRME) opened at $1.47 on Thursday. The company has a market cap of $51.12, a PE ratio of -1.77 and a beta of 0.59. The company has a debt-to-equity ratio of 1.67, a quick ratio of 4.71 and a current ratio of 5.52. Cardiome Pharma has a one year low of $1.29 and a one year high of $4.84.

An institutional investor recently raised its position in Cardiome Pharma stock. JPMorgan Chase & Co. increased its stake in Cardiome Pharma Corp (NASDAQ:CRME) (TSE:COM) by 37.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,095 shares of the biopharmaceutical company’s stock after buying an additional 42,416 shares during the period. JPMorgan Chase & Co. owned 0.49% of Cardiome Pharma worth $701,000 at the end of the most recent reporting period. 52.44% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Comments on Cardiome Pharma Corp’s FY2017 Earnings (CRME)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at

Cardiome Pharma Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with's FREE daily email newsletter.